Allen, Azar & Troy: FDA Legal Partners Streamline Enforcement Activity
This article was originally published in The Gray Sheet
Executive Summary
HHS' decision to elevate FDA warning letter oversight from the Office of Regulatory Affairs to the Office of the Chief Counsel signals an attempt to keep a tighter rein on the agency in the absence of a commissioner
You may also be interested in...
FDA Chief Counsel Warning Letter Review To Continue After Troy’s Departure
The FDA Office of Chief Counsel's review of warning and untitled letters has resulted in the rejection of approximately 5% of letters, outgoing Chief Counsel Daniel Troy said
FDA Chief Counsel Warning Letter Review To Continue After Troy’s Departure
The FDA Office of Chief Counsel's review of warning and untitled letters has resulted in the rejection of approximately 5% of letters, outgoing Chief Counsel Daniel Troy said
Paper Tigers Or Paper Bullets? FDA Curbs Repeat Warning Letters, Violations
Enforcement policies under way within FDA's Office of the Chief Counsel could eliminate the practice of issuing multiple compliance warning letters, according to agency officials